Constipation on Wegovy: finding the right laxative

What the STEP 1 data tells us about Wegovy and gut motility

The STEP 1 trial, published in the New England Journal of Medicine, remains the most cited evidence base for Wegovy's side-effect profile. Roughly one in four participants on semaglutide 2.4 mg reported constipation over the 68-week study period, a rate more than double that of the placebo group. The mechanism is fairly well understood: semaglutide slows gastric emptying and reduces the speed at which food moves through the gut. Less food volume also means less bulk reaching the colon, which reduces the natural stimulus for a bowel movement. Nausea tends to dominate the conversation about GLP-1 side effects, but constipation is quietly just as common, and it is one of the main reasons people reduce their dose or pause treatment before giving their body time to adjust.

The NHS medicines guidance for semaglutide confirms these gastrointestinal effects as expected and generally manageable, and notes that symptoms often ease after the first few weeks at any given dose. That said, dose increases tend to bring a fresh wave of GI symptoms, so constipation can return at each step of the titration schedule. Understanding what laxative options exist (and which ones fit best alongside a GLP-1) is practical preparation, not a sign that treatment is going badly. You can also find useful context on the Wegovy treatment overview page, which covers the full side-effect and lifestyle picture.

Osmotic laxatives: why they fit best with semaglutide

Osmotic laxatives work by drawing water into the large bowel, softening stool and increasing its bulk until a normal movement becomes easier. They do not stimulate muscle contractions in the gut wall, and that distinction matters when you are already taking a medicine that alters gut motility. Macrogol (sold as Movicol, CosmoCol and own-brand equivalents) is the type most commonly recommended by GPs and pharmacists as a first-line option. It is gentle, has a predictable onset of 24 to 72 hours, and is unlikely to cause cramping. Lactulose is another osmotic option, though it ferments in the gut and can worsen bloating (already a frequent complaint on Wegovy) so many people find macrogol more comfortable.

Alongside any laxative, fluid intake is the single most important self-care measure. Wegovy reduces appetite and, in practice, many people end up eating and drinking considerably less than before, including less water. Keeping a glass of water next to wherever you take your morning tablet or prepare your weekly injection makes the habit much easier to maintain, and if you are new to treatment it is worth knowing that semaglutide is also sold under an alternative name, which can be useful context when reading prescribing information or pharmacy labels. Dietary fibre from vegetables, pulses and wholegrains also supports gut transit, and the foods that work well alongside Wegovy are worth reviewing for practical meal ideas. You can also explore a structured Wegovy meal plan for guidance on getting enough fibre and protein without large food volumes.

Stimulant laxatives, bulk-forming agents and when to step up

Stimulant laxatives (senna and bisacodyl being the most familiar pharmacy options) work by triggering muscle contractions in the colon. They are effective, but they can cause cramping, and there is theoretical concern about using them long-term alongside a medicine that already alters gut muscle activity. Clinical pharmacists generally position stimulant laxatives as a second step: if macrogol alone has not helped after a few days, adding a low-dose senna can be appropriate, but it is worth flagging the combination to whoever is managing your Wegovy treatment.

Bulk-forming laxatives such as ispaghula husk (Fybogel) are sometimes recommended, but they require generous fluid intake to work properly, around 300 ml per dose. For people who are already struggling to drink enough because Wegovy has suppressed their thirst alongside their appetite, bulk-forming agents can backfire and make constipation worse if fluids are inadequate. They are best used with a deliberate hydration strategy rather than as a standalone fix. If you are unsure how your Wegovy treatment is going overall, a conversation with our clinical team can help, they review every patient's progress, not just the initial prescription. Detailed information on the injection technique and routine is also available if you want to make sure the practical side of treatment is set up well.

When laxatives are not enough: red flags and next steps

Most Wegovy-related constipation resolves with the steps above. There are, however, situations where self-management is not appropriate and a clinician needs to be involved promptly. Severe or persistent abdominal pain (particularly pain that radiates through to the back) should not be attributed to constipation and dismissed. The MHRA's January 2026 Drug Safety Update for GLP-1 medicines highlighted acute pancreatitis as a rare but serious risk: the presenting symptom is often exactly this kind of deep, persistent upper abdominal pain. Seek urgent medical attention if pain is severe, does not settle, or is accompanied by vomiting that prevents you keeping fluids down. You can report any suspected side effect via the Yellow Card scheme, run by the MHRA.

Beyond red flags, constipation that lasts more than seven to ten days, or that does not respond to two or three days of an osmotic laxative plus increased fluids, warrants a conversation with your GP or the service prescribing your Wegovy. It is also worth noting that Wegovy and its comparator semaglutide medicine have different licensed uses, for more on how they compare and why the distinction matters, the Wegovy vs Ozempic page sets out the licensing picture clearly. If you are thinking about whether Wegovy is the right treatment for you in the first place, or whether to consider alternatives, our weight management overview is a useful place to start, and you are always welcome to check your eligibility with our prescribers, the consultation is free, and they can discuss managing side effects as part of that review.